Therefore, the down-regulation of CLOCK and BMAL1 could be used as a biomarker in leukemia to support the identification of the disease; thus, the elevation of its expression compared to normal levels can be used to follow the response to treatments. The gene discussed is CLOCK; the disease is leukemia.